ORIONS Money Stocks

[Mark]

$PFSA .17, clinical trial update coming next week:

Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, announces the acceptance of an abstract for a Late Breaking Clinical Trial Update presentation at the upcoming Paris Vascular Insights (PVI) 2025, being held on December 11-13, 2025 , in Paris, France .